About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Efficacy of C1s Antibody as Complement Inhibitor in Cold Agglutinin Disease Revealed

by Dr. Enozia Vakil on April 16, 2014 at 7:42 PM
 Efficacy of C1s Antibody as Complement Inhibitor in Cold Agglutinin Disease Revealed

The C1s antibody prepared by the True North Therapeutics, Inc prevents the destruction of human red blood cells exposed to plasma samples of patients with a type of autoimmune hemolytic anemia. The article entitled "TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinin disease patient autoantibodies" was published on-line in the journal Blood earlier this month. TNT003 is the murine analog of True North's lead humanized monoclonal antibody drug candidate, TNT009, for which the company plans to initiate the first clinical program in 2015.

Advertisement

In ex vivo studies using plasma samples from patients with a type of AIHA known as cold agglutinin disease (CAD), True North demonstrated that red blood cells exposed to patient samples contained high levels of Complement proteins deposited on the cell surface. True North showed that by inhibiting Complement deposition on the red blood cell membrane, TNT003 prevented the red blood cells from being engulfed by macrophages, immune cells responsible for clearing Complement-coated cells and debris from the blood. TNT003 also prevented direct red blood cell lysis driven by a CAD sample that contained unusually high levels of autoantibodies, suggesting that a Complement inhibitor like TNT003 could be efficacious in severe cases of CAD.

"By selectively shutting down the Classical Complement pathway with an antibody, the main drivers of anemia in CAD have been reduced in this preclinical study. Using TNT003 and a large number of 40 patient samples, we were able to deepen the field's understanding of the Complement system's role in this rare disease. The study strengthens the hypothesis that such an approach could be beneficial in this rare patient population," stated Sandip Panicker, PhD, C1s Program Lead and senior author on the journal article in Blood.
Advertisement

TNT003 inhibits C1s, a member of the Complement family of plasma proteins, which, upon activation, trigger a powerful enzymatic cascade that destroys and removes pathogens from the circulation. However, aberrant Complement system activation has been described in numerous autoimmune settings in which antibodies that attack self, known as autoantibodies, play a role in disease pathogenesis. Like other forms of AIHA, CAD is a disorder in which anti-red blood cell antibodies bind to and lead to the destruction of patient red blood cells through Complement system activation.

Dr. Panicker further stated, "As Complement system activity is the only known driver of red blood cell destruction in patients with CAD, the results in the study published in Blood provide compelling evidence for the development of TNT009, the company's lead humanized monoclonal antibody, for the treatment of CAD and potentially other forms of AIHA, for which no approved therapies exist."



Source: Eurekalert
Font : A-A+

Advertisement

Advertisement
Advertisement

Recommended Readings

Latest Research News

Disrupted Circadian Rhythm Elevates the Risk of Parkinson's Disease
Trouble with sleep and the body's clock may increase your risk for Parkinson's, as per a new study.
A Wake-Up Call for Women — Hot Flashes Could Point to Alzheimer's Risk
New study uncovers a link between nocturnal hot flashes and Alzheimer's risk in menopausal women, suggesting a potential biomarker.
Breakthrough Brain-Centered Approach Reduces Chronic Back Pain
Our discovery revealed that a minority of individuals attributed their chronic pain to their brain's involvement.
New Statement to Protect Athletes' Health Published
Relative Energy Deficiency in Sport syndrome is overlooked by athletes and can be worsened by 'sports culture' due to its perceived short-term performance benefits.
Brain Circuits That Shape Bedtime Rituals in Mice
New study sheds light on the intrinsic, yet often overlooked, role of sleep preparation as a hardwired survival strategy.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
MediBotMediBot
Greetings! How can I assist you?MediBot
×

Efficacy of C1s Antibody as Complement Inhibitor in Cold Agglutinin Disease Revealed Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests